Skip to main content

Genome Therapeutics Raises $9M in Common Stock Placement

NEW YORK, Sept. 30 (GenomeWeb News) - Genome Therapeutics has raised approximately $9 million in net proceeds after expenses ($9.55 million total) through a private placement of common stock, the company said today.

Approximately 3.8 million new shares of Genome Therapeutics common stock were issued to several new institutional shareholders, led by Domain Public Equity Partners. Investors also received warrants to purchase 1.9 million shares at an exercise price of $3.48 per share. The warrants are exercisable for a period of five years.

According to Steven Rauscher, CEO of Genome Therapeutics, the company will use the additional financing to support clinical studies of its lead product candidate, Ramoplanin, currently in clinical development for the prevention, treatment, and control of hospital-based infections.

The Scan

WHO OKs Emergency Use of Sinopharm Vaccine

The World Health Organization has granted emergency approval for Sinopharm's SARS-CoV-2 vaccine, the Guardian reports.

Scientific Integrity Panel to Meet

According to the Associated Press, a new US scientific integrity panel is to meet later this week.

Trying in the Eye

NPR reports that a study of Editas Medicine's CRISPR therapy for Leber congenital amaurosis has begun.

PLOS Papers on Cerebellum Epigenetics, Copy Number Signature Tool, Acute Lung Injury Networks

In PLOS this week: epigenetics analysis of brain tissue, bioinformatics tool to find copy number signatures in cancer, and more.